Skip to content

Bioventus BVS Allowance for doubtful accounts

Allowance for doubtful accounts at other companies

Medtronic logo
MedtronicMDT
Globus Medical logo
Globus MedicalGMED
Enovis logo
EnovisENOV
IAR
Integra LifeSciencesIART
Axogen logo
AxogenAXGN
OrthoPediatrics logo
OrthoPediatricsKIDS

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's allowance for doubtful accounts.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's allowance for doubtful accounts?
Bioventus (BVS) reported allowance for doubtful accounts of $3.06M in Q1 2026.
How has Bioventus's allowance for doubtful accounts changed year-over-year?
Bioventus's allowance for doubtful accounts increased by 8.0% year-over-year, from $2.83M to $3.06M.
What is the long-term trend for Bioventus's allowance for doubtful accounts?
Over 5 years (2020 to 2025), Bioventus's allowance for doubtful accounts has grown at a -6.2% compound annual growth rate (CAGR), from $3.99M to $2.9M.